| NCT02855944 | III | Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy) | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Colorado, Georgia |
| Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT03398655 | III | Platinum resistant ovarian cancer | A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer | View Drugs | Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Vermont, Wisconsin |
| Ofranergene Obadenovec | VB-111 | Endothelin promoter-apoptotic receptor gene therapy | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02091141 | IIa | Advanced solid tumors with ALK mutations or high TMB | My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents | View Drugs | Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin |
| Alectinib | ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 | ALK kinase inhibitor | | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells |
|
| NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | View Drugs | California, Florida, Louisiana, Texas |
| Anlotinib | AL3818 | VEGFR2/3 kinase inhibitor | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02419417 | IIa | Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations | A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies | View Drugs | California, Colorado, Massachusetts, Oregon, Pennsylvania, South Carolina |
| BMS-986158 | BET inhibitor BMS-986158 | BET inhibitor | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02502266 | II/III | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | View Drugs | Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin |
| Cediranib | AZD2171, Cediranib maleate, Recentin | VEGFR1-3 kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT02272998 | II | Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations | Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1) | View Drugs | Ohio |
| Ponatinib | multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 | Multi-targeted kinase inhibitor |
|
| NCT02079740 | II | Advanced solid tumors with KRAS or NRAS mutations (in expansion) | An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors | View Drugs | Massachusetts |
| Navitoclax | Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 | Bcl-2, Bcl-XL, and Bcl-w inhibitor | | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor |
|
| NCT01037790 | II | Advanced solid tumors with CCND1/2 amplification, CDK4/6 mutation, or other G1/S alterations | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | View Drugs | Pennsylvania |
| Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor |
|
| NCT01953926 | II | Advanced solid tumors with activating HER2 mutations | An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. | View Drugs | Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Wisconsin |
| Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor |
|
| NCT02203513 | II | Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer | View Drugs | Maryland |
| Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
| NCT02312245 | II | Platinum resistant or refractory ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | View Drugs | Arizona, Florida, Minnesota |
| Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
| NCT02568267 | II | Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | View Drugs | Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington |
| Entrectinib | TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101 | ALK, TRK, ROS1 kinase inhibitor |
|
| NCT02693535 | II | Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, ERBB2, FGFR1-3, FLT-3, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMB | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | View Drugs | Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington |
| Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | | Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor | | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor | | Temsirolimus | Torisel, CCI-779 | mTOR inhibitor | | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | | Vemurafenib | RO5185426, PLX4032, Zelboraf | BRAF kinase inhibitor |
|
| NCT02465060 | II | Advanced solid tumors with alterations in AKT, BRAF, cKIT, CDK4 AMP, CDK6 AMP, EGFR, ERBB2 AMP, FGFR1-4, FGFR1-4 AMP, MET, MET AMP, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2 | Molecular Analysis for Therapy Choice (MATCH) | View Drugs | Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming |
| Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | | Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | | Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | | Larotrectinib | Trk inhibitor LOXO-101 | pan-Trk kinase inhibitor | | Osimertinib | Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib | EGFR kinase inhibitor | | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | | Sapanisertib | INK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228 | TORC1/2 kinase inhibitor | | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | | Ulixertinib | BVD-523, ERK inhibitor BVD-523 | ERK inhibitor | | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist |
|
| NCT02628067 | II | Advanced solid tumors with high MSI | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | View Drugs | California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas |
| Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02576444 | II | Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations | A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors | View Drugs | Connecticut, Massachusetts, Ohio, Tennessee |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Capivasertib | Akt inhibitor AZD5363 | pan-AKT inhibitor | | Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT01827384 | II | Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53 | Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors | View Drugs | Colorado, Georgia, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Everolimus | Afinitor, Certican, RAD001, Zortress | mTOR inhibitor | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor | | Veliparib | ABT-888 | PARP inhibitor |
|
| NCT02554812 | II | Advanced solid tumors (in ovarian expansion) | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | View Drugs | California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | PD-0360324 | anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 | CSF1R antagonist and tumor-associated macrophage inhibitor | | PF-04518600 | anti-OX40 antibody PF-04518600 | Stimulates OX40 to increase T cell activation and immune response |
|
| NCT02832167 | II | Advanced solid tumors | An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | View Drugs | Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02571725 | II | Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb) | A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer | View Drugs | Florida, New Mexico, Ohio, Virginia |
| Olaparib | AZD2281, Lynparza | PARP inhibitor | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02873962 | II | Platinum resistant or partially sensitive ovarian cancer | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | View Drugs | Massachusetts |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT01851369 | II | Advanced solid tumors and granulosa cell ovarian cancer (in expansion) | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | View Drugs | Maryland |
| Methoxyamine | TRC102 | Base excision repair inhibitor | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent |
|
| NCT02901899 | II | Platinum resistant ovarian cancer | An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer | View Drugs | Illinois |
| Guadecitabine | DNA methyltransferase inhibitor SGI-110, SGI-110 | DNA methylation inhibitor | | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity) | A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | View Drugs | Arizona, Florida, Minnesota |
| MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis |
|
| NCT02873975 | II | Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations | A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency | View Drugs | Massachusetts |
| Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | View Drugs | California |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Ass | |
